Wednesday, BioView Ltd. revealed the interim results of its internal clinical trial of non-invasive diagnostic test under development for early detection of lung cancer. BioView lung cancer test is based on morphological and genetic analysis of sputum samples and is running on BioView DUETTM automated scanning platform.
In the trial, a total of 76 sputum samples were collected from four groups of patients and were blindly scanned and analyzed morphologically and genetically, with fluorescent probes exclusively licensed to BioView. These results were then compared to the actual data received from the hospital of the patients' condition.
The samples included 32 cases of lung cancer patients and 44 samples taken from people with no clinical evidence of lung cancer. Thirty one of the thirty two sick patients were correctly diagnosed as "Abnormal" and thirty-six of forty four healthy people were correctly diagnosed as "Normal", the company noted.
For comments and feedback: editorial@rttnews.com